- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05048758
Adverse Childhood Experiences in Alcohol Use Disorder
Vulnerability for Alcohol Use Disorder After ACE: the Role of Stress Sensitivity, Emotion Processing, Cue Reactivity and Cognitive Functions in Relapse Risk
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The aim of this study is to examine the impact of ACE on stress sensitivity, cue-reactivity, and emotion processing in individuals with AUD at a longitudinal level. For this, participants (excluding healthy controls) from the first project (see https://clinicaltrials.gov/ct2/show/NCT03758053) will be re-examined after 2 to 2.5 years to explore the involvement of these mechanisms in relation to (long-term) relapse risk, which is a central issue in substance use disorders. Furthermore, we will investigate cognitive functions, specifically response inhibition and working memory, in the relationship between ACE and AUD. Additional participants may be recruited to mitigate sample attrition from the first project and to achieve the desired sample size. To assess cognitive functions and data from new participants in relation to relapse risk, we will perform a 3-month follow-up.
Neural correlates of stress-sensitivity, emotion processing, alcohol cue-reactivity and cognitive functions will be assessed using fMRI. Furthermore, blood and saliva samples will be used to assess biological and physiological mechanisms (e.g. salivary cortisol level or genetic markers of AUD and possible gene-environment-interactions).
The current project is interested in the extent to which ACE severity modulates neural activation in specific brain regions during the execution of fMRI paradigms as well as alcohol-related measures (e.g., craving and alcohol consumption). Of particular interest is the question whether these neural and alcohol-related measures are associated with relapse risk.
55 individuals with AUD and varying levels of ACE will be examined using interviews, questionnaires, fMRI tasks as well as saliva and blood samples. Update from 29/03/2023: the relationships of interest will be examined using a dimensional approach to the predictor variable (ACE). Thus, participants will not be divided into two groups (no or mild ACE vs. moderate to severe ACE) as originally planned, but will instead be treated as one group with varying levels of ACE. The new sample size (n = 55) is based on an updated sample size calculation for a linear regression (two-tailed) using the following input parameters: f² = 0.15 (moderate effect size), alpha error = 0.05, and power = 80%. All ethical votes and informed consents of participants will be obtained according to the declaration of Helsinki.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Baden-Württemberg
-
Mannheim, Baden-Württemberg, Germany, 68159
- Klinik für Abhängiges Verhalten, Zentralinstitut für Seelische Gesundheit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Male and female
- Age between 18 and 65
- Normal or correctable eyesight
- Sufficient ability to communicate with the investigators, to answer questions in oral and written form
- "Fully Informed Consent"
- "Written Informed Consent"
- Individuals with alcohol use disorder according to DSM-5 or 'heavy drinking' (alcohol intake > 40g/ more than 5 days (women) & 60g/ more than 5 days (men) and varying levels of adverse childhood experiences
Exclusion Criteria:
- Withdrawal of the declaration of consent
- Exclusion criteria for an MRI scan (pregnancy, metal implants, etc.)
- Severe internal, neurological and psychiatric comorbidities
- Pharmacotherapy with psychoactive substances within the last 14 days (except treatment with SSRI/SNRIs for at least 28 days)
- Axis-I disorder according to ICD-10 and DSM 5 (except tobacco and alcohol use disorder, substance abuse with less than 2(11) criteria according to DSM-5, mild depressive episode, adaptation disorder and specific phobia within the last 12 months)
- Positive urin drug screening (cannabis, amphetamine, opiates, benzodiazepines, cocaine)
- Withdrawal symptoms (CIWA-R > 7)
- Intoxication at time of investigation (breathalyzer > 0.3‰)
- Suicidal tendency or potential danger for others
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Individuals with AUD + varying levels of ACE
Individuals with alcohol use disorder (AUD) and varying levels of adverse childhood experiences (ACE)
|
No intervention
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
fMRI to assess group and within-subjects differences in task-specific brain activation patterns: Stress-sensitivity
Time Frame: fMRI measurement at one day only (day of fMRI experiment)
|
Stress-sensitivity: Imaging Stress Task to assess neural activation patterns during mental arithmetic tasks with negative feedback
|
fMRI measurement at one day only (day of fMRI experiment)
|
|
fMRI to assess group and within-subjects differences in task-specific brain activation patterns: Emotion processing
Time Frame: fMRI measurement at one day only (day of fMRI experiment)
|
Emotion-processing: emotional face-/form-matching task to assess neural activation patters of emotion processing
|
fMRI measurement at one day only (day of fMRI experiment)
|
|
fMRI to assess group and within-subjects differences in task-specific brain activation patterns: Alcohol cue-reactivity
Time Frame: fMRI measurement at one day only (day of fMRI experiment)
|
Alcohol cue-reactivity: pictures of alcoholic beverages to assess neural alcohol-cue reactivity
|
fMRI measurement at one day only (day of fMRI experiment)
|
|
fMRI to assess group differences in task-specific brain activation patterns: Response inhibition
Time Frame: fMRI measurement at one day only (day of fMRI experiment)
|
Response inhibition: Stop Signal Task (variation of go/no-go) to assess response inhibition.
|
fMRI measurement at one day only (day of fMRI experiment)
|
|
fMRI to assess group differences in task-specific brain activation patterns: Working memory
Time Frame: fMRI measurement at one day only (day of fMRI experiment)
|
Working memory: n-back task (continuous performance) to assess working memory function.
|
fMRI measurement at one day only (day of fMRI experiment)
|
|
Long-term alcohol consumption
Time Frame: 2 - 2.5 year follow-up after first project
|
Self-report in longitudinal sample measured with the LDH interview
|
2 - 2.5 year follow-up after first project
|
|
Short-term alcohol consumption
Time Frame: 3-month follow-up after current project
|
Self-report in whole sample measured with the Form 90 interview
|
3-month follow-up after current project
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hormonal stress response using salivary cortisol level
Time Frame: Normal awakening response on a subject's regular week-day (0, 0.5, 8 and 14 hours after wake-up)
|
Collection of saliva on a subject's regular week-day for the individual's normal cortisol awakening response and circadian rhythm (basal hypothalamic-pituitary-adrenal-function at 0, 0.5, 8 and 14 hours after wake-up). Cortisol awakening reaction, area under the curve and slope will therefore be calculated [nmol/L] |
Normal awakening response on a subject's regular week-day (0, 0.5, 8 and 14 hours after wake-up)
|
|
Hormonal stress response using salivary cortisol level
Time Frame: day of fMRI experiment, at -45, -22, -10 minutes before and 35, 45, 60, 75 and 90 minutes after onset of stress induction
|
Time course of salivary cortisol level.
Area under the curve and slope will be calculated [nmol/L]
|
day of fMRI experiment, at -45, -22, -10 minutes before and 35, 45, 60, 75 and 90 minutes after onset of stress induction
|
|
GWAS and especially glutamatergic, serotonergic single-nucleotide polymorphisms
Time Frame: Blood sample at one day only (day of fMRI experiment)
|
Genomic DNA using 40ml EDTA-blood
|
Blood sample at one day only (day of fMRI experiment)
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Sabine Vollstaedt-Klein, PhD, Central Institute of Mental Health, Mannheim
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GRK2350-B5-P2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Use Disorder
-
Technische Universität DresdenCharite University, Berlin, Germany; Central Institute of Mental Health, MannheimRecruitingAlcoholism | Methamphetamine-dependence | Substance Use Disorders | Cocaine Use Disorder | Alcohol Use Disorder (AUD) | Cannabis Use Disorder | Amphetamine Use DisorderGermany
-
Washington State UniversityRecruitingNicotine Use Disorder | Alcohol Use Disorder (AUD)United States
-
Indiana UniversityPatient-Centered Outcomes Research InstituteRecruitingAdolescent | Alcohol Use | Mild Alcohol Use Disorder | Mild Substance Use DisorderUnited States
-
University of North Carolina, Chapel HillCompletedAlcohol Use Disorder, Mild | Alcohol Use Disorder, ModerateUnited States
-
University of BernRecruitingAlcohol Use Disorder (AUD) | Substance Use Disorder (SUD) | Cocaine Use Disorder (CUD)Switzerland
-
Université du Québec à Trois-RivièresCompletedAlcohol Use, Unspecified | Alcohol Use Disorder, MildCanada
-
Woebot HealthStanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
University of Wisconsin, MadisonNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Not yet recruitingAlcohol Use Disorder | Alcohol Use Disorder (AUD)United States
-
Technische Universität DresdenCharite University, Berlin, Germany; Central Institute of Mental Health, MannheimRecruitingAlcoholism | Substance Use Disorders | Alcohol Use Disorder (AUD)Germany
-
University of Notre DameNational Institute on Alcohol Abuse and Alcoholism (NIAAA)RecruitingAlcohol Use | Opioid Use Disorder | Alcohol Use Disorder | Opioid UseUnited States
Clinical Trials on No intervention
-
Hopital FochNot yet recruitingInterstitial Lung DiseaseFrance
-
Wave NeuroscienceCompletedAutistic DisorderUnited States
-
University of Alabama at BirminghamCompletedInflammatory Bowel Diseases | Colorectal Cancer | Diverticular Diseases | Social BehaviorUnited States
-
Janssen Research & Development, LLCCompletedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States, Poland
-
Hospital Universitario La Paz3MVX CCB and Agaplesion Markus Krankenhaus, Frankfurt a.M., Germany.; Department...RecruitingEmbolism | Atrial Fibrillation | Arrhythmia | Stroke, Acute | Stroke Sequelae | AblationSpain
-
Southern California College of Optometry at Marshall...Ohio State University; University of Houston; Alcon Research; University of Waterloo and other collaboratorsCompletedContact Lens Complication | Contact Lens Acute Red Eye | Contact Lens Related Corneal Infiltrate (Disorder) | Contact Lens-Induced Corneal Fluorescein StainingUnited States, Canada
-
Huashan HospitalZhejiang Cancer Hospital; Shanghai Zhongshan Hospital; Tongji Hospital; Qilu Hospital... and other collaboratorsRecruitingHead and Neck Squamous Cell Carcinoma | Patient Derived Organoid | Drug Sensitive Test in VitroChina
-
China Medical University HospitalUnknownIntention to Stay, Turnover Behavior
-
University of Dublin, Trinity CollegeCompleted